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ABSTRACT

Objective Sjögren’s disease (SjD) is an autoimmune
disease characterised by inflammatory destruction of
exocrine glands. Patients with autoantibodies to Ro/SSA
(SjDRo+) exhibit more severe disease. Long non-coding
RNAs (lncRNAs) are a functionally diverse class of non-
protein-coding RNAs whose role in autoimmune disease
pathology has not been well characterised.
Methods Whole blood RNA-sequencing (RNA-seq) was
► Additional supplemental
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Ro+
n=27 Ro/SSA positive (SjD ) and healthy controls
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(HCs; n=27). Bioinformatics and pathway analyses of
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differentially expressed (DE) transcripts (log2 fold change
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≥2 or ≤0.5; padj<0.05) were used to predict lncRNA
function. LINC01871 was characterised by RNA-seq
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analyses of HSB-2 cells with CRISPR-targeted LINC01871
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deletion (LINC01871−/−) and in vitro stimulation assays.
Results Whole blood RNA-seq revealed autoantibody-
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specific
transcription profiles and disproportionate
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downregulation of DE transcripts in SjD cases relative to
HCs. Sixteen DE lncRNAs exhibited correlated expression
with the interferon (IFN)-regulated gene, RSAD2, in SjDRo+
(r≥0.65 or ≤−0.6); four antisense lncRNAs exhibited IFN-
regulated expression in immune cell lines. LINC01871
was upregulated in all SjD cases. RNA-seq and pathway
analyses of LINC01871−/− cells implicated roles in
cytotoxic function, differentiation and IFNγ induction.
LINC01871 was induced by IFNγ in a myeloid cell line and
regulated by calcineurin/NFAT pathway and T cell receptor
(TCR) signalling in primary human T cells.
Conclusion LINC01871 influences expression of many
immune cell genes and growth factors, is IFNγ inducible, and
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INTRODUCTION
Sjögren’s disease (SjD) is a heterogeneous
autoimmune disease that affects ~0.7% of the
worldwide population with a female-to-male

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Sjögren’s disease (SjD) is an understudied heteroge-

neous autoimmune disease generally characterised
as extreme dryness of the eyes and mouth caused
by immune-mediated destruction of exocrine glands.
⇒ Identifying transcripts that are differentially expressed in SjD subphenotypes and have functional
implications in disease pathology (especially undercharacterised long non-coding RNAs (lncRNAs))
provides important new insights into the disease
mechanisms that drive SjD and identify potential
biomarkers of different subphenotypes.

WHAT THIS STUDY ADDS
⇒ Pathway analyses of whole blood transcriptomes from

patients with SjD that are either positive or negative for
the hallmark autoantibody, anti-Ro (SjDRo+ vs SjDRo−),
and healthy controls suggest these two SjD subphenotypes may have different mechanisms of disease pathology: interferon-mediated disease in SjDRo+ patients
and T cell-driven disease in SjDRo− and SjDRo+ patients.
⇒ Identified the lncRNA, LINC01871, as differentially
expressed in SjD and important for T cell function.

HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ Study clearly implicates dysregulation of lncRNAs

as important mechanisms driving both interferon-
mediated and T cell-driven pathology of SjD. As
such, it provides critical insights for future studies
aimed at identifying biomarkers of SjD for clinical
diagnosis. The approaches described herein also
provide a roadmap to guide future studies in the
discovery and functional characterisation of novel
lncRNAs with potential disease implications.

disparity of greater than 9:1.1–3 Extreme dry
eyes and mouth are hallmark symptoms of SjD
caused by chronic inflammation, lymphocytic
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infiltration, and subsequent destruction of lacrimal and
salivary glands.4 5 Many patients with SjD also experience
extraglandular complications including pulmonary and
kidney dysfunction, neuropathy, debilitating fatigue,
arthritis/arthralgia, leucocytoclastic vasculitis and an
increased risk of 9-
fold to 20-
fold of non-
Hodgkin’s
lymphoma.5 Although the aetiology and pathological
mechanisms remain unknown, it is widely hypothesised
that genetic susceptibility likely influences disease onset,
progression and heterogeneity in the context of specific,
but not yet defined, environmental conditions.6 7
Research classification criteria for SjD require focal
lymphocyte sialoadenitis of a biopsied salivary gland
and/or circulating autoantibodies to the RNA-binding
protein, Ro60/SSA/TROVE-
2 and/or the ubiquitin
ligase protein, Ro52/TRIM21.8–11 Circulating anti-
Ro/
SSA antibodies are common in SjD (~60%–70%; SjDRo+)
and have been correlated with the upregulation of
interferon (IFN)-stimulated genes (ie, IFN signature),
increased lymphocyte infiltration of glands, more severe
salivary gland involvement, increased prevalence of
systemic extraglandular disease and higher risk of developing non-Hodgkin’s lymphoma.12–14 In contrast, patients
with anti-Ro autoantibody-negative SjD (SjDRo−) lack the
IFN signature and have a lower risk of lymphoma, but
exhibit increased dryness measures, peripheral nervous
system involvement and evidence of T cell-
driven
pathologies.15–17
Long non-coding RNAs (lncRNAs) are a diverse group
of non-protein-coding RNAs greater than 200 nucleotides in length that modulate chromatin remodelling,
transcription, and/or post-
transcriptional modifications.18 Transcriptome profiling studies have identified
numerous differentially expressed (DE) lncRNAs in autoimmune diseases, including SjD.19–25 These and similar
studies applied expression correlation analyses with
protein-coding RNAs (pcRNAs) to gain insights into the
molecular roles of DE lncRNAs, but precise functional
mechanisms remain undefined for many of the ~150 000
reported lncRNAs in the NONCODE database (noncode.
org). For example, the lncRNA, negative regulator of the
IFN response (NRIR), was shown to impair hepatocyte
responses to IFN, but was also reportedly upregulated
and functioned to positively regulate IFN responses
in monocytes from patients with systemic sclerosis.26 27
Nuclear enriched abundant transcript 1 (NEAT1) positively
regulates BAFF-mediated type I IFN activation of B cells
in lupus-prone mice, mitogen-activated protein kinase
(MAPK) signalling in cells from patients with SjD and
inflammation signalling through TLR4.22 28 29 IFNG-AS1
(TMEVPG1 or NeST) increases Th1 responses in patients
with SjD.30 Together, these studies suggest previously
uncharacterised DE lncRNAs may yield important mechanistic implications and/or serve as novel biomarkers for
SjD and other human diseases.
This study leveraged whole blood RNA-
sequencing
(RNA-
seq) analyses coupled with bioinformatics
pathway and co-
expression correlation analyses to
2

identify and differentiate important regulators of the
IFN signature-dominant SjDRo+ subphenotype from the
T cell-driven pathologies shared by SjDRo+ and SjDRo−.
To this end, we identified four antisense lncRNAs that
were overexpressed in the SjDRo+ and co-
expressed
with IFN-regulated transcripts. LINC01871, a previously
uncharacterised lncRNA, was found to be overexpressed
in both SjD subphenotypes and regulated through both
IFNγ and calcineurin/NFAT signalling. Collectively, this
study provides insights into the pathways that influence
SjDRo+ and SjDRo− subphenotypes and mechanistic roles
of several lncRNAs implicated in immune cell regulation
and SjD pathogenesis.
METHODS
See online supplemental materials and methods.
RESULTS
RNA-seq was performed using RNA from globin-depleted
whole blood from 50 patients with SjD (27 SjDRo+, 23
SjDRo−) and 27 healthy controls (HCs) (online supplemental table 1). After quality control, a total of 37 821
transcripts were analysed for DE (log2 fold change
(log2FC) ≥1 or ≤−1; false discovery rate-adjusted p value
(padj)≤0.05). Four analyses were performed: (1) all SjD
cases (SjDAll) versus HCs (figure 1A; online supplemental
table 2); (2) SjDRo+ versus HCs (figure 1B; online supplemental table 3); (3) SjDRo− versus HCs (figure 1C; online
supplemental table 4); (4) SjDRo+ versus SjDRo− (online
supplemental table 5). The SjDAll versus HC, SjDRo+ versus
HC and SjDRo− versus HC analyses identified 4451, 2377,
and 6379 DE transcripts, respectively, with nearly equal
representation of pcRNAs and lncRNAs (figure 1D–F;
online supplemental table 6). The majority of genes
were downregulated in all three SjD DE transcript sets
relative to HCs (figure 1D–F), indicating repression of
gene expression, lack of appropriate upregulation of
gene expression or substantially different blood cellular
composition in SjD. Differential blood cellularity, mostly
involving leucocytopenia, has been described in SjD.16 31
Deconvolution was performed using quantiseqr32 to assess
whether differences in cell type composition between
the three datasets may confound interpretations of the
RNA-seq results. Significant differences between SjDRo+
or SjDRo−, and HCs were only observed in macrophages
and monocytes (online supplemental figure 1).
Differential expression of pcRNAs
A total of 3097 unique pcRNAs were DE across all three
analyses (figure 1E). In the SjDAll versus HC and SjDRo+
versus HC analyses, the most upregulated DE pcRNAs
were IFN-
stimulated genes: RSAD2, IFI44L and IFI27
(figure 1A,B; table 1; online supplemental tables 2 and
3).33 The IFN-stimulated gene, S100A8, was upregulated
in all three analyses. In contrast, many of the upregulated
DE pcRNAs in the SjDRo− versus HC analysis, including
ATG10 and UQCRB, were involved in protein processing
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

RMD Open: first published as 10.1136/rmdopen-2022-002672 on 1 December 2022. Downloaded from http://rmdopen.bmj.com/ on December 22, 2022 by guest. Protected by copyright.

RMD Open

Figure 1 Protein-coding (pc)RNAs and long non-coding (lnc)RNAs are differentially expressed in the whole blood of SjD
cases compared with healthy controls (HCs). (A–C) Differentially expressed (DE) transcripts from whole blood RNA-sequencing
analysis of (A) all SjD cases (SjDAll; n=50), (B) anti-Ro positive SjD cases (SjDRo+; n=27) or (C) anti-Ro negative SjD cases
(SjDRo−; n=23) compared with HCs (n=27). Y-axis shows the −log10 of the FDR-adjusted p value (padj); x-axis shows the log2 of
the fold change (FC). Black dots indicate the top three upregulated and downregulated pcRNAs and lncRNAs in the analysis.
Grey dots indicate the top three upregulated and downregulated pcRNAs and lncRNAs in the other analyses. (D–F) Distribution
of (D) all DE transcripts, (E) DE pcRNAs or (F) DE lncRNAs across the three analyses. Black text indicates total DE transcripts;
red text indicates upregulated transcripts; green text indicates downregulated transcripts. (G–L) Hierarchical clustering of
annotated module aggregates across individual SjDRo+ (purple) or SjDRo− (green) cases. Displayed individual modules had DE
of >20% of constitutive transcripts in at least one case. Colour gradient indicates the proportion of DE transcripts ranging from
100% increased (red) to 100% decreased (blue), respective to HCs. FDR, false discovery rate; SjD, Sjögren’s disease.

and cell metabolism (figure 1C; table 1; online supplemental table 4).
Many of the most downregulated DE pcRNAs from the
SjDRo− versus HC analysis were also DE in the SjDAll versus
HC and SjDRo+ versus HC analyses (figure 1A–C; table 1),
indicative of common pathways across disease subphenotypes. Further, several of these transcripts, including
CORT, PRAMEF25, KRT39, ERICH4 and BANF2, have not
been previously reported as DE in SjD.
Pathway analyses of DE transcripts
Gene Set Enrichment Analysis34 35 (online supplemental tables 7 and 8), Ingenuity Pathway Analysis (IPA)
(online supplemental figure 2A and tables 9–11) and
the BloodGen3 module approach previously developed
for whole blood lupus studies36–38 (figure 1G–L; online
supplemental figure 2B–D) were performed using the
DE transcript lists to gain insights into the functional
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

similarities and differences between SjDRo+ and SjDRo−.
Consistent with previous reports, the pathway analyses
of the DE transcripts from the SjDRo+ versus HC analysis
strongly indicated upregulated type I IFN signalling and
other pro-inflammatory pathways (figure 1G,I,J; online
supplemental figure 2A–C and table 12). Pathways of
significance for the SjDRo− versus HC analysis included
antigen receptor, cytokine and calcium/cAMP signalling
(online supplemental figure 2A,B,D and table 12). Examination of all gene module sets from the BloodGen3
approach revealed significant heterogeneity among
individual cases and, apart from the type I IFN signature, no clear segregation based on autoantibody status.
The majority of subjects with SjD did exhibit increased
expression of genes in the oxidative phosphorylation
module set (figure 1H). Further, a subset of subjects
with SjD, irrespective of autoantibody status, showed
3
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RNA-seq analysis of whole blood from SjD cases reveals common and subphenotype-specific differently expressed pcRNAs and lncRNAs
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Bold indicates top three upregulated and downregulated pcRNAs and lncRNAs in each analysis.
FDR, false discovery rate; lncRNAs, long non-coding RNAs; Log2FC, log2 fold change; Padj, FDR-adjusted p value; pcRNAs, protein-coding RNAs; RNA-seq, RNA sequencing; SjD, Sjögren’s
disease; SjDAll, all SjD cases; SjDRo−, anti-Ro negative SjD; SjDRo+, anti-Ro positive SjD.
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increased expression of genes in the erythroid module set
(figure 1K), perhaps consistent with recent work showing
the presence of erythrocyte mitochondria in juvenile
systemic lupus erythematosus.39 Collectively, these analyses suggest that the disease pathologies of SjDRo+ involve
a prominent IFN signature that is absent from, and less
likely to influence disease pathology of, SjDRo−. However,
the heterogeneous stratification of SjDRo+ and SjDRo−
subjects with respect to other gene module sets suggests
that multiple mechanisms likely contribute to SjD, with
shared mechanisms of cellular metabolism and immune
cell dysfunction.
Differential expression of lncRNAs
A total of 660 unique DE lncRNAs were shared across
all three whole blood RNA-
seq analyses; 97 lncRNAs
were unique in the SjDRo+ versus HCs; 1114 lncRNAs
were unique in the SjDRo− versus HCs (figure 1F; online
supplemental table 6). The most upregulated DE antisense lncRNAs in the SjDRo+ versus HCs were also upregulated in the SjDAll versus HC analysis and are antisense to
pcRNAs implicated in type I IFN signalling: AC004551.1
(antisense spanning the genes OAS1, OAS2 and OAS3,
therefore, named OAS123-AS1; ENSG00000257452) and
AP001610.1 (directly overlapping antisense to MX1, therefore, named MX1-AS1; ENSG00000228318) (figure 1A,B;
table 1; online supplemental tables 2 and 3).33 The IFN-
inducible lncRNA, NRIR,26 27 was also upregulated in
both SjDAll versus HCs and SjDRo+ versus HCs (online
supplemental tables 2 and 3). Significant upregulation
of NRIR, OAS123-AS1 and MX1-AS1 in SjDAll and SjDRo+
was validated by quantitative reverse transcription PCR
(RT-qPCR) in an independent cohort of 22 cases with SjD
(14 SjDRo+, 8 SjDRo−) and 24 HCs (online supplemental
figure 3A–C). AC099063.1 (directly overlapping antisense to the type II IFN responsive gene, GBP5; therefore,
named GBP5-AS1; ENSG00000237568), CALHM6-AS1
and UQCRB-AS1 were upregulated DE antisense lncRNAs
in all three RNA-
seq analyses (figure 1A–C; table 1;
online supplemental tables 2–4). GBP5-AS1 upregulation was validated by RT-
qPCR in the independent
SjDRo+and trended in SjDAll (online supplemental figure
3E). As observed with the pcRNAs, many of the downregulated antisense lncRNAs were shared among the three
analyses, such as TNR-AS1, AXDND1-AS1 and CASC23
(figure 1A–C; table 1; online supplemental tables 2–4).
Several lncRNAs, including LINC01871 and
AC245060.5, were also DE across all three RNA-seq analyses (figure 1A–C; table 1; online supplemental tables
2–4). LINC01871 upregulation was validated by RT-qPCR
in the independent cohort (online supplemental figure
3D). Two DE lncRNAs were uniquely upregulated in the
SjDRo+ versus HCs: LINC00487 and U62317.3 (figure 1B;
table 1; online supplemental table 3). AC016629.3 was
unique to and the most upregulated DE lncRNA in the
SjDRo− versus HCs (figure 1C; table 1; online supplemental table 4). Lastly, the SjDRo− versus HC analysis
exhibited the most downregulated lncRNAs with two
6

subphenotype-specific transcripts: AC017002.3 and
AC091027.2 (figure 1C; table 1; online supplemental
table 4).
Identification and cell type-specific expression of IFN-related
lncRNAs
Pearson’s correlation analyses were performed using the
highly DE IFN-stimulated pcRNA, RSAD2 and DE transcript lists from the SjDAll, SjDRo+, SjDRo−, and HC datasets to identify RSAD2-correlated transcripts (r>0.65 or
<−0.6; p<0.05) (figure 2A; online supplemental table 13).
Numerous IFN-responsive pcRNAs and 16 lncRNAs from
the SjDRo+ DE transcript list correlated with RSAD2 expression, including MX1-AS1, NRIR, BISPR, OAS123-AS1 and
IRF1-AS1 (figure 2A; online supplemental tables 13 and
14).33 40 CYTOR, an lncRNA implicated in cancer and
autophagy,41–43 was also correlated. Five anti-correlated
lncRNAs were also identified, including ZNF793-AS1,
which was DE in SjDAll versus HC and SjDRo− versus HC
RNA-seq analyses.
level expression of transcripts that were
Individual-
both DE in the whole blood RNA-
seq analyses and
correlated with RSAD2 expression segregated into IFN
high, moderate and low clusters that corresponded with
anti-Ro antibody status (figure 2B). Correlated expresresponsive lncRNAs in SjDRo+
sion of RSAD2 and IFN-
subjects further implicated these lncRNAs as potential
regulators of IFN responses. Interestingly, Blueprint
Epigenome cell type-specific RNA-seq data from 62 cell
types revealed lower and more cell type-restricted expression of these lncRNAs, relative to IFN-responsive pcRNAs
(online supplemental figure 3G).
Modulation of lncRNAs in response to IFN in vitro
RT-qPCR was performed with RNA from Kasumi-3 (early
myeloid) cell lines stimulated with IFNα or IFNγ over a
48-hour time course to determine if the RSAD2 correlated and DE lncRNAs were modulated by IFN. NRIR
and the IFN-
stimulated pcRNAs, RSAD2 and CMPK2
were coordinately upregulated in response to IFNα in
Kasumi-3 cells (figure 2C). OAS123-AS1, MX1-AS1 and
GBP5-AS1 were also upregulated, but their induction
preceded upregulation of respective pcRNAs, OAS1,
MX1 or GBP5 (figure 2C). IFNγ stimulation also upregulated NRIR expression by 6 hours, and OAS123-AS1, MX1-
AS1 and GBP5-AS1 expression by 1.5 hours (figure 2D).
Observed kinetics of the IFN response suggests that these
antisense lncRNAs may positively regulate the spatially
linked pcRNAs.
Identification of dysregulated lncRNAs common across SjD
subphenotypes
Identifying and characterising lncRNAs that are
common among different SjD subphenotypes may
provide new insights into common disease mechanisms.
Fourteen of the 660 shared DE lncRNAs identified in
the whole blood RNA-seq analyses were overexpressed
(figure 1F; online supplemental table 6). Twelve were
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

RMD Open: first published as 10.1136/rmdopen-2022-002672 on 1 December 2022. Downloaded from http://rmdopen.bmj.com/ on December 22, 2022 by guest. Protected by copyright.

RMD Open

Figure 2 Differentially expressed (DE) interferon (IFN)-responsive lncRNAs were coordinately modulated with associated
pcRNAs and correlated with antibody status of SjD cases. (A) RSAD2 correlation analysis of the normalised RNA-seq data
from the SjDRo+-only primary expression matrix (r≥0.65 or ≤−0.6; p<0.05). Type I IFN-responsive pcRNAs and other pcRNAs
and lncRNAs of interest are indicated. (B) Individual-level expression of transcripts that were correlated with RSAD2 expression
and DE in any of the whole blood RNA-seq analyses. Z-scores were computed using scale function in R, after calculating
fold change of expression relative to healthy controls. K-means clustering (K=3) segregated cases by high, moderate and low
IFN status, and are shown relative to patient antibody status. pcRNAs and lncRNAs of interest are indicated. (C,D) RT-qPCR
analysis of indicated DE transcripts in Kasumi-3 cells stimulated with (C) universal type I IFN (IFNα; 150 U/mL) or (D) IFNγ
(2800 U/mL) from 0 to 48 hours. Target lncRNAs are shown in blue and respective pcRNAs in grey (n>3). lncRNAs, long non-
coding RNAs; pcRNAs, protein-coding RNAs; RNA-seq, RNA sequencing; RT-qPCR, quantitative reverse transcription PCR;
SjD, Sjögren’s disease; SjDRo+, anti-Ro positive SjD; SjDRo−, anti-Ro negative SjD.

antisense or sense-intronic transcripts, including GBP5-
AS1, CALHM6-AS1, LARP7-AS1 (miR302CHG) and
UQCRB-AS1, and two were long intergenic non-coding
RNAs, LINC01871 and AC245060.5 (table 1; online
supplemental tables 2–4). Minimal information was available on AC245060.5, but LINC01871 was reported as DE
in multiple cancer studies, autoinflammatory diseases, T
cells and monocytes (data derived from Gene Expression
Atlas; online supplemental figure 3F),44–49 making it a
transcript of interest in human disease.
LINC01871, located at the 2p25.1 locus, has low exonic
conservation among vertebrates, multiple isoforms found
only in humans and low protein-coding potential (online
supplemental note).50 The surrounding genomic interval
has an enrichment of H3K27ac epigenetic marks, DNaseI
hypersensitivity and transcription factor binding indicative of active transcription. Consistently, LINC01871 is
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

strongly expressed in mature CD4+ and CD8+ T cells, class
switched memory B cells, plasma cells, natural killer (NK)
cells and haematopoietic progenitor cells (data derived
from Blueprint Epigenome RNA-seq data; online supplemental figure 3H). Conversely, regulatory T cells and
most B cells have low basal expression of LINC01871 and
early lineage T cells (CD3− thymocytes) do not express
LINC01871. Analysis of publicly available single-
cell
RNA-seq data of minor salivary gland tissue revealed that
LINC01871 is most highly expressed in tissue-resident T
cell subtypes and NK cells (online supplemental figure
3I,J).51 52 These data confirm the expression of this
lncRNA in immune cells present in SjD-affected tissues,
indicating potential relevance to disease pathology.
Interrogation of publicly available GeneFriends,53
FuncPred54 and lncRNA2function55 databases found
that LINC01871 expression was correlated with pcRNAs
7
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Figure 3 Loss of LINC01871 disrupts basal expression of genes involved in immune cell regulation. (A) LINC01871 correlation
analysis of normalised RNA-seq data from the SjDRo−-only primary expression matrix (r≥0.7 or ≤−0.6; p<0.05). Transcripts
implicated in immune function or SjD pathology are indicated. (B) Quantitative PCR screen of LINC01871 expression in HSB-
2 single-cell clones after CRISPR-targeted deletion of LINC01871. (C) Differentially expressed transcripts from the RNA-seq
analysis of HSB-2 clone 4121 (hereafter LINC01871−/−) relative to HSB-2 parental cell line. Y-axis shows the −log10 of the FDR-
adjusted p value (padj); x-axis shows the log2 of the fold change (FC). Black dots indicate independently replicated transcripts
of interest. (D) Levels of indicated surface or intracellular proteins, reported as mean fluorescence intensity (MFI), in HSB-2
parental cells (black) and LINC01871−/− cells (blue); n=3; unpaired t-test where *p<0.05, **p<0.01 or ***p<0.001. (E) Growth
curve analysis of HSB-2 parental cells (black) and LINC01871−/− cells (blue) from 0 to 96 hours; n=3; unpaired t-test where
*p<0.05 or **p<0.01. (F) Concentration of indicated secreted protein in supernatant collected from HSB-2 parental cells (black)
and LINC01871−/− cells (blue) at 96 hours; n>6; unpaired t-test where *p<0.05 or ****p<0.0001. FDR, false discovery rate; RNA-
seq, RNA sequencing; SjD, Sjögren’s disease; SjDRo−, anti-Ro negative SjD.

implicated in IFNγ stimulation, T cell activation and
differentiation, myeloid cells and dendritic cells
(online supplemental tables 15–17). In this SjD cohort,
LINC01871 expression was highest in the SjDRo− subjects
(online supplemental figure 3D).
Pearson’s correlation analyses were performed using
the DE transcript list from the SjDRo− versus HC analysis
to identify transcripts of specific interest to immune cell
activation and regulation correlated with LINC01871
(r>0.7 or <−0.6; p<0.05) (figure 3A; online supplemental
table 18). Of specific interest, CAMK2N1 and NFAT5 are
both directly regulated by calcium signalling,56 while
EOMES, GZMA and FGFBP2 are important for cytotoxic
immune responses.33 Consistently, Gene Ontology (GO)
Enrichment Analysis,57 performed using the LINC01871-
correlated DE transcripts list, identified GO terms implicating LINC01871 in immune system function, leucocyte
8

and lymphocyte activation, and IFNγ production (online
supplemental table 19).
Functional analysis of LINC01871 by RNA-seq analysis of a
clonal CRISPR-targeted LINC01871 deletion
To explore the function of LINC01871, CRISPR-guided
RNAs were designed to target the LINC01871 interval in
early T cell lineage HSB-2 cell line, which constitutively
express LINC01871 (figure 3B; online supplemental
figure 4A and table 20). Clones of the CRISPR-edited
HSB-2 cells were screened for LINC01871 deletion by
RT-qPCR, identifying clone 4121 (hereafter referred to
as LINC01871−/−) as having complete deletion of the
targeted LINC01871 interval confirmed by Nanopore
sequencing (figure 3B; online supplemental figure 4B,C
and tables 21 and 22).
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RNA-seq analysis of LINC01871−/− cells relative to unedited HSB-2 parental cells identified 1166 DE transcripts
(log2FC≥1 or ≤−1; padj≤0.05) (figure 3C; table 2; online
supplemental table 23). Loss of LINC01871 disproportionately decreased the expression of pcRNAs (~3:1); perturbations of ncRNAs were more equally distributed (online
supplemental table 24). Notably, several transcripts that
were positively correlated with LINC01871 in the whole
blood RNA-seq analyses, such as CCL5 (log2FC=−3.46;
padj=9.82e-12) and FGFBP2 (log2FC=−3.54; padj=1.62e-17)
(online supplemental tables 2–4,18), were significantly
downregulated in LINC01871−/− cells (figure 3C; table 2;
online supplemental table 23). In addition, loss of
LINC01871 completely abrogated the expression of 127
transcripts, including adaptive immunity genes TNFSF8
(CD30L), IL22, CD27 and LYN (table 2; online supplemental table 23).
Consistent with the whole blood SjD RNA-seq correlation analyses and database functional predictions, GO
Enrichment Analysis and IPA of the LINC01871−/− DE
transcripts identified several pathways involved in
immune cell development and signalling, including
Th1/Th2 cells, T/B cell signalling and leucocyte extravasation, as well as pathways impacting growth and cell
survival (table 2; online supplemental figure 4D–J and
tables 19 and 25). Predictions of such wide-
ranging
impacts suggest that LINC01871 may act as a broad regulator impacting many immune cell pathways.
Validation of transcript expression and characterisation of
growth and protein expression in LINC01871−/− cells
RT-qPCR was used to validate the DE of 32 transcripts using
independent biological replicates of the LINC01871−/−
cells compared with unmodified HSB-2 cells. Twenty-nine
of the selected genes, including LINC01871, exhibited
significant changes in gene expression (online supplemental figure 5A–D). Two of the remaining three transcripts trended but did not reach significance: SLAMF7
and CSF2 (online supplemental figure 5A and D).
LINC01871−/− cells also displayed significant and stable
changes in the expression of five cell surface proteins
(CD8a, CD30, CXCR3, CD226 and CD44) and two intracellular transcription factors (T-bet and Aiolos) important in immune cell function (figure 3D; online supplemental figure 5E–K).58 59
Given the observed DE of transcripts involved in
cell proliferation, the growth characteristics of the
LINC01871−/− cells were also examined. While early
growth rates of the LINC01871−/− cells appeared comparable with the unmodified HSB-
2 cells, the growth
rate of LINC01871−/− cells slowed with time in culture,
suggesting that deletion of LINC01871 may perturb the
secretion of growth factors (figure 3E). Consistently,
several key secreted proteins/growth factors, including
CSF1 (M-CSF protein) and CSF2 (GM-CSF protein), were
reduced in the supernatants from the LINC01871−/− cells
compared with the unmodified HSB-2 cells (figure 3F;
online supplemental figure 5D). IGFBP4, a secreted
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

inhibitor of insulin-like growth factor (IGF) with functions in inflammation and growth regulation,60 was also
depleted. FLT3L, which encodes the protein Flt3-L, a
critical dendritic cell cytokine that acts in concert with
GM-CSF,61 62 trended toward a decrease. Interestingly, the
pleiotropic cytokine, LIF (leukaemia inhibitory factor),
was markedly increased, implicating LINC01871 as a
negative regulator of this gene.
Perturbations in the concentrations of several proteins
commonly associated with cell−cell interactions and extravasation were also observed. The extracellular adhesion
and endoprotease proteins, MMP2 and MMP9,63 64 were
both significantly reduced in the media of LINC01871−/−
cells (figure 3F). However, MMP2 gene expression was
increased in the RNA-seq analysis (log2FC=3.85; online
supplemental figure 5D), suggesting some dysregulation of MMP2 protein secretion in the LINC01871−/−
cells. Changes in the expression of MMP9 could not be
replicated by qPCR, perhaps due to differential isoform
detection by qPCR. Soluble ICAM, a marker of vascular
inflammation,65 was also significantly decreased. Overall,
deletion of LINC01871 in a T cell line caused widespread
disruption of diverse cellular proteins, including the
disruption of basal level expression of many proteins
involved in adaptive immune responses, cell migration,
adhesion and extravasation.
LINC01871 expression is modulated by IFNγ in a myeloid cell
line
LINC01871 correlation analyses, bioinformatics data and
CRISPR-edited LINC01871−/− in vitro studies suggested
that LINC01871 may play a role in both IFN and immune
cell activation pathways, specifically IFNγ signalling.
Because HSB-2 cells do not respond to in vitro IFNγ
stimulations and LINC01871 was reported to be overexpressed in acute myeloid leukaemia,46 we used Kasumi-3
cells to determine if LINC01871 expression is regulated
by universal type I IFN (IFNα) and/or IFNγ (type II IFN)
stimulations. IFNα stimulation did not induce LINC01871
in Kasumi-3 cells, but robustly induced the expression of
IFN-inducible genes, TBX21 and IRF7 (figure 4A,B). In
contrast, IFNγ upregulated LINC01871 expression (peak
12-fold induction), as well as the IFN-stimulated genes,
TBX21, IL6R, IDO2 and IRF7 (figure 4C,D), thus demonstrating that LINC01871 expression in myeloid cells is
regulated by type II IFN signalling.
LINC01871 expression is regulated by calcineurin/NFAT
signalling
To further test the hypothesis that LINC01871 may play a
role in adaptive immune cell activation, specifically T cell
activation, LINC01871−/− and parental HSB-2 cells were
stimulated with phorbol 12-myristate 13-acetate and ionomycin (PMA/I) and the modulation of LINC01871, IL2,
IFNG, CD8A, TBX21 and CSF1 expression was assessed
by RT-qPCR. PMA/I was used to mimic T cell receptor
(TCR) signalling because HSB-2 cells lack a functional
TCR.66 67 PMA/I increases intracellular calcium without
9
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Table 2 CRISPR deletion of LINC01871 alters the expression of several immune regulatory transcripts
Immune regulation
and function

Growth signalling/
cancer regulation

Gene (protein) symbol

Log2FC

Padj

LYN

−10.392

1.24E-16

CD109

−9.707

2.05E-14

TNFSF15

−9.598

4.64E-14

IL17RB

−9.324

1.87E-13

IL22

−8.080

1.70E-09

IKZF3 (Aiolos)

−7.158

1.62E-34

PDCD1 (PD-1)

−6.243

1.07E-06

CD27

−6.128

1.20E-04

TNFSF8 (CD30L)

−5.727

8.29E-04

LAG3

−4.684

1.04E-14

CD79A

−4.091

2.66E-08

EGR2

−3.925

5.74E-62

THEMIS

−3.770

5.85E-162

CD8A

−3.683

4.03E-34

CCL5

−3.456

9.82E-12

FOXP3

−3.064

1.78E-03

IRF5

−2.959

1.19E-10

TNFRSF8 (CD30)

−2.537

3.47E-44

SLAMF7

−2.398

1.90E-52

TBX21 (T-Bet)

−2.066

2.45E-23

IL6ST

−1.820

2.16E-21

CXCR3

−1.728

2.68E-18

TNFRSF4

1.910

1.37E-09

CD44

1.924

1.68E-174

TGFBR3

2.069

8.65E-16

CD226

2.750

1.96E-80

SELL (CD62L)

3.061

1.82E-15

HAVCR2

3.139

1.95E-87

CCR4

3.816

4.47E-08

KLF2

4.043

4.13E-60

TOX2

4.353

2.58E-138

CCR2

4.893

9.69E-13

TIGIT

5.531

2.31E-08

SLAMF1 (CD150)

5.726

4.86E-84

IGFBP4

−12.476

3.61E-32

CSF1 (M-CSF)

−7.356

5.58E-16

PTPN13

−5.998

4.19E-05

TLR2

−5.914

7.51E-05

PRKAR2A

−5.899

2.08E-56

MMP9

−5.096

9.32E-117

FSCN1

−5.003

0.00E+00

PDGFD

−4.730

7.54E-03

GZMB

−4.688

2.93E-02

P2R×7

−4.190

1.17E-08

ADCY6

−4.163

5.86E-21

FGFBP2

−3.543

1.62E-17

CSF2 (GM-CSF)

−3.052

6.62E-48

TNF

−1.631

1.22E-88

CD28

1.614

7.59E-30

1

2

3

4

5

6

7

8

9

10

11

12

Continued
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Table 2 Continued
Gene (protein) symbol

Log2FC

Padj

XCL1

1.636

1.92E-09

TLR1

1.674

4.87E-02

LIF

2.613

2.15E-171

ITGA6

3.072

0.00E+00

HPGD

3.517

1.88E-37

MMP2

3.851

1.17E-02

ITGAM

4.198

4.15E-03

IL7R

4.393

1.41E-02

PTGDR2

4.399

1.27E-83

ALOX15B

5.189

5.42E-03

PTGDR

5.460

1.02E-10

HPGDS

7.992

1.99E-09

1

2

3

4

5

6

7

8

9

10

11

12

Ro−

Genes in bold denote correlation with LINC01871 in SjD
(online supplemental table 18).
1. Th1 pathway; 2. Th2 pathway; 3. Th1/Th2 activation; 4. CD8 cytotoxic/cytokines; 5. Treg/Th17; 6. T cell development; 7. T cell exhaustion; 8. associated with autoimmune disease;
9. molecular mechanisms of cancer; 10. proliferation/crosstalk; 11. extravasation/migration; 12. prostaglandin pathway.
FDR, false discovery rate; log2FC, log2 fold change; Padj, FDR-adjusted p value; SjD, Sjögren’s disease; SjDRo−, anti-Ro negative SjD; Treg, regulatory T cell.

surface receptor engagement, leading to activation of
the calmodulin-dependent protease, calcineurin, as well
as protein kinase C (PKC), and subsequent downstream
transcriptional activation through multiple pathways
including NFAT and NFκB.66 67 LINC01871 expression
was undetectable in LINC01871−/− cells. Parental HSB-2
cells showed marked LINC01871 downregulation after
6 hours of PMA/I stimulation that returned to near basal
levels after ~36 hours (figure 4E). Targets of calcineurin/
NFAT signalling, IL2 and IFNG, exhibited robust inductions in parental HSB-2 cells, indicating normal stimulation (figure 4F,G). LINC01871−/− cells showed an
increased induction of IL2 expression, but an impaired
induction of IFNG in response to PMA/I (figure 4F,G).
This was not due to differences in basal expression as
neither transcript was expressed in unstimulated cells.
CD8A expression increased modestly in HSB-2 cells after
PMA/I stimulation but decreased in LINC01871−/− cells
(figure 4H). TBX21 and CSF1 both exhibited a higher
magnitude of induction in LINC01871−/− cells compared
with HSB-2 cells (figure 4I,J); however, this was likely due
to lower basal expression in LINC01871−/− cells, resulting
in a larger fold change induction.
Flow cytometry was used to determine if loss of
LINC01871 also modulated PMA/I-
mediated expression of cell surface proteins. PMA/I stimulation induced
CD8A surface expression in parental HSB-
2 cells but
did not change CD8A expression in the LINC01871−/−
cells, likely because of abrogated CD8A expression in
LINC01871−/− cells (online supplemental figure 5L). Loss
of LINC01871 prevented the PMA/I-mediated downregulation of CD30 and CXCR3 surface expression observed
in parental HSB-
2 cells (online supplemental figure
5M,N). In contrast, PMA/I upregulated the surface
expression of CD226 and CD44 in both parental HSB-2
and LINC01871−/− cells (online supplemental figure
5O,P).
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

To determine if the PMA/I-
mediated downregulation of LINC01871 resulted from calcineurin activation,
parental HSB-2 cells were treated with the calcineurin-
specific inhibitor, FK506 (tacrolimus),68 or rapamycin
(mTOR signalling inhibitor in the same molecular class
as FK506), prior to PMA/I stimulation. Treatment with
FK506 alone did not alter LINC01871 expression, but
presence of FK506 during PMA/I stimulation restored
LINC01871 expression nearly to that of unstimulated
cells (figure 4K). Rapamycin had no effect on LINC01871
expression. In addition, FK506 mitigated PMA/I-
mediated induction of NFAT-regulated genes, IL2 and
IFNG (figure 4L,M), and partially inhibited induction of
two genes modulated in LINC01871−/− cells, TBX21 and
CSF1 (figure 4O,P). Rapamycin also partially impaired
PMA/I-
mediated induction of IL2, but had no effect
on TBX21 and CSF1. Both FK506 and rapamycin caused
significant impairment of IFNG expression (figure 4M),
indicating this pathway is regulated by both calcineurin
and mTOR signalling. Neither inhibitor affected PMA/I-induced expression of CD8A (figure 4N). Overall, these
data show that LINC01871 expression is downregulated in
T cells in response to direct calcineurin/NFAT activation.
Human T cells regulate LINC01871 expression by calcineurin/
NFAT signalling
To further examine the role of LINC01871 in T cells,
the expression of LINC01871 and other transcripts of
interest were measured in human T cells purified from
healthy donor PBMCs treated with FK506 or DMSO and
stimulated with PMA/I using RT-qPCR. As in the HSB-2
cells, PMA/I repressed LINC01871 expression in purified
human T cells, beginning at 1.5 hours, and maintained
repression 12 hours post-treatment (figure 5A), an effect
that was abrogated by FK506. PMA/I-
treated human
donor T cells also exhibited similar transcriptional
11
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Figure 4 LINC01871 is modulated by interferon (IFN)γ and calcineurin/NFAT signalling in immune cell lines. (A−D) RT-qPCR
analysis of LINC01871 (A and C), TBX21 (A and C), IRF7 (B and D), IL6R (B and D) and IDO2 (B and D) in Kasumi-3 cells
stimulated with either (A,B) universal type I IFN (IFNα; 150 U/mL) or (C,D) IFNγ (2800 U/mL) from 0 to 48 hours. Expression is
reported as fold change relative to unstimulated controls. (E−J) RT-qPCR analysis of LINC01871 (E), IL2 (F), IFNG (G), CD8A
(H), TBX21 (I) and CSF1 (J) in LINC01871−/− cells (blue) and HSB-2 parental (black) cells stimulated from 0 to 48 hours with
PMA/I (100 ng/mL; 1000 ng/mL). Expression is reported as fold change relative to unstimulated controls; n=3; unpaired t-test
where **p<0.01, ***p<0.001 or ****p<0.0001. (K−P) RT-qPCR analysis of LINC01871 (K), IL2 (L), IFNG (M), CD8A (N), TBX21
(O) and CSF1 (P) in HSB-2 parental cells stimulated from 0 to 12 hours with PMA/I (100 ng/mL; 1000 ng/mL) with and without
FK506 (2.5 µM; purple) or rapamycin (Rap; 2.5 µM; orange). Expression is reported as fold change relative to unstimulated
inhibitor controls; n=3; paired t-test where *p<0.05, **p<0.01, ***p<0.001 or ****p<0.0001. Black * indicates FK506 with PMA/I
relative to PMA/I alone and grey * indicates Rap with PMA/I relative to PMA/I alone. PMA/I, phorbol 12-myristate 13-acetate
and ionomycin; RT-qPCR, quantitative reverse transcription PCR.

regulation of IL2, IFNG, CD8A and TBX21, relative to
HSB-2 cells (figure 5B–E).
Engagement of the TCR triggers a complex signalling
cascade, including the activation of multiple signalling
effectors including MAPKs, PKC and calcineurin.66 In
contrast to our findings using PMA/I, LINC01871 expression was previously shown to increase in response to anti-
CD3/CD28-activated TCR signalling in human T cells
(online supplemental figure 3F; unpublished data).69
12

To address this, LINC01871 expression was assessed in
purified human T cells stimulated with anti-CD3/CD28
antibodies. TCR signalling decreased LINC01871 expression at early time points (figure 5F), although to a lower,
but significant, degree compared with PMA/I stimulation. However, LINC01871 expression increased twofold
to threefold with longer anti-
CD3/CD28 stimulation
(48 hours), perhaps mimicking chronic TCR stimulation
in vitro. FK506 treatment of anti-CD3/CD28-stimulated
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672
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Figure 5 LINC01871 is modulated by IFNγ and calcineurin/NFAT signalling in purified human T cells. (A–E) Negatively selected
human donor T cells were treated with DMSO or 2.5 µM FK506 overnight, then stimulated with PMA/I (100 ng/mL; 1000 ng/
mL) for 12 hours. Expression of LINC01871 (A), IL2 (B), IFNG (C), CD8A (D) and TBX21 (E) was assessed by RT-qPCR and
reported as fold change relative to DMSO-treated cells; n=4; paired t-test where *p<0.05, **p<0.01, ***p<0.001 or ****p<0.0001.
Grey lines indicate PMA/I. Black lines indicate PMA/I with FK506 treatment. (F–I) Negatively selected human donor T cells
were treated with either DMSO or 2.5 µM FK506 overnight, then stimulated with anti-CD3/CD28 for 48 hours. Expression of
LINC01871 (F), IL2 (G), IFNG (H) and CSF1 (I) was assessed by RT-qPCR and reported as fold change relative to DMSO-treated
cells at each time point; n=4; paired t-test where *p<0.05, **p<0.01, ***p<0.001 or ****p<0.0001. Grey lines indicate anti-CD3/
CD28. Black lines indicate anti-CD3/CD28 with FK506 treatment. IFN, interferon; PMA/I, phorbol 12-myristate 13-acetate and
ionomycin; RT-qPCR, quantitative reverse transcription PCR.

T cells shifted the kinetics of downregulation of
LINC10871 at early time points, but augmented expression at late time points. As expected, anti-CD3/CD28
stimulation induced expression of IL2 and IFNG, which
was nearly abrogated by FK506 treatment (figure 5G,H).
CSF1 expression also exhibited increased expression with
prolonged TCR stimulation in the presence of FK506
treatment (figure 5I). In conclusion, LINC01871 expression is modulated in human T cells in response to calcineurin/NFAT and TCR signalling. The overexpression of
LINC01871 in SjD, coupled with the alterations observed
in LINC01871−/− cells and its regulation by both IFNγ and
calcineurin/TCR signalling, suggest that this lncRNA
plays a role in immune cells that may be relevant to autoimmune disease.
DISCUSSION
Dysregulated immune and salivary gland functions,
including a prominent IFN signature, are implicated
in the pathogenesis of SjD.12 70 Consistently, the whole
blood RNA-seq from this study revealed IFN signalling
dysregulation in the SjDRo+. In contrast, pathway analyses
were indicative of T cell-driven disease mechanisms in
the SjDRo−. Interestingly, the DE transcripts from both
the SjDRo+ and SjDRo− exhibited overall repression of
transcript expression relative to HCs, including downregulation of many lncRNAs. Further, direct comparison of
SjDRo+ and SjDRo− yielded surprisingly few DE transcripts
(online supplemental table 5), the majority of which
were IFN-
induced genes. Given previously reported
differences in the absolute numbers of specific immune
cell types in patients with SjD,16 the observed minor
alterations in the abundance of immune cell types by
deconvolution in this study (online supplemental figure
Joachims ML, et al. RMD Open 2022;8:e002672. doi:10.1136/rmdopen-2022-002672

1), and the significant differences in the mean ages of
the SjD and HC subjects from this study (online supplemental table 1), it is possible that these and other observations from this study may be influenced by the slight
differences in the percentages of different immune cell
types in the limited peripheral blood samples available
from SjD cases subphenotyped based on Ro autoantibody status. Future studies using carefully matched case–
control samples would be needed to resolve this limitation, as well as further improve our understanding of SjD
heterogeneity.
Although recent studies have revealed important regulatory roles of several lncRNAs in immune responses and
autoimmunity (reviewed in 71 72), few studies have investigated the potential roles of lncRNAs in SjD pathogenesis.
The IFN signalling pathway is tightly regulated, requiring
genetic ‘on/off’ switches to rapidly activate or suppress
transcription in response to changing cellular environments.33 More recent studies have identified lncRNAs
that function as important regulators of IFN signalling,
autoimmunity and cancer. Conflicting reports of NRIR
functioning as a positive regulator of IFN-inducible gene
expression in monocytes,26 27 but a negative regulator of
expression in hepatocellular carcinomas,27 suggest that
NRIR expression is subject to cellular and context-specific
regulatory effects. In this study, NRIR was overexpressed
in whole blood of SjDRo+ and induced by both type I and
type II IFN stimulation in vitro. We also demonstrated that
three previously uncharacterised antisense lncRNAs were
IFN responsive: OAS123-AS1, MX1-AS1 and GBP5-AS1.
Our kinetic data suggest that these antisense lncRNAs are
rapidly induced in response to IFNs and their induction
may act as a massive upregulation signal to induce their
respective pcRNAs. The precise mechanisms of action
13
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for these novel antisense lncRNAs will require further
studies.
We identified 15 other lncRNAs (online supplemental
table 14) that were also correlated with IFN-inducible
gene expression, including BISPR (BST2 IFN-stimulated
positive regulator), which is implicated in the regulation
of tetherin function,40 and CYTOR, which interacts with
microRNAs to modulate numerous signalling systems
implicated in cancer.41–43 CYTOR, BISPR, NRIR73 and
LINC0048774 (table 1) were previously reported as upregulated in patients with SjD. Interestingly, LINC00487
resides ~50 kb upstream of NRIR, suggesting the entire
genomic region containing LINC00487/NRIR/CMPK2/
RSAD2 is subject to IFN regulation. However, other
lncRNAs reportedly overexpressed in SjD, such as IFNG-
AS1,30 NEAT122 and PTV1,23 were not DE in our analyses
(online supplemental tables 2–4). Further studies will be
required to elucidate the mechanisms of action of undefined lncRNAs.
In this study, we identified LINC01871 as overexpressed
in all patients with SjD. Deep bioinformatics data mining,
expression correlation analyses in the whole blood SjDRo−
RNA-
seq dataset, and pathway analyses all implicated
LINC01871 as a potential regulator of T cell activation
and differentiation. Loss of LINC01871 in a T cell line
altered the expression of numerous transcripts implicated
in innate and adaptive immune function. Dysregulation
of LINC01871 in SjD may play a role in the T cell-driven
pathogenesis of SjD by impacting leucocyte migration and
extravasation (CD44, MMP2, MMP9, ITGAM, SELL), IFNγ
signalling (CXCR3) and cellular growth pathways (CSF1,
CSF2).58 59 75 Notably, many of the pcRNAs perturbed due
to LINC01871 deletion have been previously implicated
in the pathogenesis of SjD and/or autoimmunity. MMP9
is reportedly overexpressed in the salivary gland of
patients with SjD,63 64 and CXCR3 is strongly induced by
IFNγ and highly expressed in the T cells of patients with
SjD.75 CSF2 is also reportedly elevated in the plasma of
patients with SjD.76 Further, LINC01871 is overexpressed
in several human cancers, highlighting the importance
of this transcript in the regulation of multiple cellular
processes.44–47
Finally, we observed that LINC01871 was negatively
regulated by both short-
term calcineurin/NFAT and
TCR signalling in both a T cell line and primary human T
cells, but positively regulated during long-term TCR stimulation. While it is tempting to assume an overall downregulation of LINC01871 based on the use of PMA/I
(figure 5A), this pharmacological stimulus is much
more powerful and broadly acting than TCR signalling,
modelled herein by cross-linking with anti-CD3/CD28
beads (figure 5F). The extent and duration of calcineurin activation after TCR signalling are distinct from
that of PMA/I treatment, and this difference is readily
appreciated in the bimodal regulation of LINC01871
through longer stimulation and the effect of FK506 as an
augmenter, rather than an inhibitor, of expression at late
time points. These seemingly contradictory outcomes
14

point to complex regulation, likely by more than one
pathway (eg, IFNγ, figure 4C). Further, we speculate
that the upregulation of LINC01871 during chronic or
continual TCR stimulation is consistent with LINC01871
dysregulation in response to dysregulated T cell function
in autoimmune diseases. Dutta et al recently showed that
calcineurin also has NFAT-independent activity by recruitment to the TCR and regulation of ICAM-1-dependent
cell adhesion.77 Our observed kinetic-dependent differences in LINC01871 regulation in the primary human
T cells emphasise the need for careful dissection of the
involved molecular pathways in the future.
Our data clearly implicate the dysregulation of lncRNAs
as an important mechanism driving the IFN-mediated
and/or T cell-driven pathology of SjD. Understanding
the underlying differential regulation of immunomodulatory gene expression in clinical subphenotypes of
SjD will provide critical insights for future identification of biomarkers and/or development of novel therapeutic treatments. Further, the approaches described
in this study provide a roadmap to guide future studies
in the discovery and functional characterisation of novel
lncRNAs with potential disease implications.
Data availability
Whole blood RNA-seq datasets generated during this study
will be made available through the Databases of Genotypes and Phenotypes controlled-access study phs002723.
v1.p1 after publication of this manuscript. RNA-seq datasets generated from the CRISPR-edited HSB-2 cell lines
will be made available through the NCBI Sequence Read
Archive after publication of this manuscript. Alternatively, access to the RNA-seq data will be made available
in accordance with consent and data transfer/use agreement from the Oklahoma Medical Research Foundation
by request to the corresponding author, Dr Christopher
J Lessard (chris-lessard@omrf.org). All other data associated with this study were publicly available and cited in
the manuscript and URLs provided as an online supplemental note.
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Participant whole blood RNAs used in this study were
obtained from the Oklahoma Medical Research Foundation Sjögren’s Research Clinic (OMRF-SRC) with Institutional Review Board (IRB) approval. Request for samples
must be submitted to Dr A Darise Farris (principal
investigator of OMRF-SRC; Darise-Farris@omrf.org).
Access will depend on limited sample availability and
will require IRB approval and completion of a material
transfer agreement. LINC01871−/− CRISPR-edited HSB-2
cell line generated in this study will be made available
by request to the corresponding author (Dr Christopher
Lessard; chris-lessard@omrf.org) after a material transfer
agreement is completed. Sequences of the primers used
to create and/or evaluate this cell line are provided in the
online supplemental tables and can be ordered through
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